Joanna Smart
Direttore/Membro del Consiglio presso Verso Biosense Group Ltd.
Profilo
Joanna Smart is currently a Director at Verso Biosense Group Ltd.
Prior to this, she was the Executive Chairman and CEO at Oxford Cancer Biomarkers Ltd.
Posizioni attive di Joanna Smart
| Società | Posizione | Inizio |
|---|---|---|
Verso Biosense Group Ltd.
 Verso Biosense Group Ltd. Financial ConglomeratesFinance Verso Biosense Group Ltd. is a British dormant company that was founded in 2016. The private company is based in Milton, UK. and has subsidiaries in United Kingdom. | Direttore/Membro del Consiglio | 09/04/2021 |
Precedenti posizioni note di Joanna Smart
| Società | Posizione | Fine |
|---|---|---|
Oxford Cancer Biomarkers Ltd.
 Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | Amministratore Delegato | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Verso Biosense Group Ltd.
Verso Biosense Group Ltd. Financial ConglomeratesFinance Verso Biosense Group Ltd. is a British dormant company that was founded in 2016. The private company is based in Milton, UK. and has subsidiaries in United Kingdom. | Finance |
Oxford Cancer Biomarkers Ltd.
Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | Health Services |
- Borsa valori
- Insiders
- Joanna Smart
